Clinical Study | Office of Clinical Research

D6070c00001- A Phase 1 Multicenter, Open-Label, Dose-Escalation And Dose-Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Immunogenicity, And Antitumor Activity Of Medi9447 Alone And In Combination With Durvalumab In Adult Subjects

Posted Date: May 15, 2019

Investigator: Trisha Wise-Draper
Specialties: Cancer, Lung Cancer, Pancreatic Cancer
Type of Study: Drug

To assess the safety and tolerability, describe any dose-limiting toxicity (DLT), and determine the MTD or the highest protocol-defined dose for oleclumab when administered as a single agent and in combination with durvalumab in subjects with selected advanced solid tumors.

Criteria:

To Be Eligible: Age 18 Or Older, Nonpregnant/Nonbreastfeeding, Must Have Crc, Pancreatic Adenocarcinoma, Or Nsclc, No Uncontrolled Current Illness Or Malignancy Within 2 Years

Keywords:

Pancreatic Cancer, Nsclc, Phase I, Solid Tumor

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List